AllDocs -> cancers

lymphoma 1581 Primary Mediastinal B-cell Lymphoma Grand Rounds 9/24/2004 Caron Rigden, M.D. Case Presentation 34 y/o male presented with a 3 week history of sob, chest pain, and increased facial swelling He also reported intermittent fevers, no chills, increased fatigue, decreased appetite, and a 10 pound weight loss over the previous month PMH- none NKDA Medications- none Social- single, lives alone, 1 ppd tobacco, &nbs...

lymphoma 1581 What is the current role of Allogeneic Stem Cell Transplantation in Lymphoma ? What is the current role of Allogeneic Stem Cell Transplantation in Lymphoma ? UNDEFINED Theoretical Justification for Allogeneic Transplantation Tumor free graft Undamaged Stem Cells Avoidance of MDS/secondary AML Graft versus lymphoma effect Problems with Allogeneic Transplantation in Lymphoma Lack of suitable donors High Treatment Related Mortality Regimen related toxicity Infection GVHD Increased Costs NHL and Transplant Relapsed diffuse large B-cell Relapsed follicular center (low ...

lymphoma 1581 Cutaneous T-Cell Lymphoma Shachar Peles M.D. Hematology & Oncology Grand Rounds September 26, 2003 Case Presentation 52 year old Left forearm rash for 4 years Intermittent erythematous patches Left forearm rash flared up – nodular, rapidly progressing Case Presentation PMH: Polio – age 4 Cyst removal near parotid 30 yrs ago Meds: Centrum Silver, Gingko All: NKDA SH: 1ppd x 25 years. Social Etoh. FH: F – died age 92 – CHF M – Alzheimer’s &n...

lymphoma 1581 Primary CNS Lymphoma Geoffrey L. Uy Case Presentation A 47 y/o WF who presented to BJH with a 1 ½ year history of visual problems. She complained of flashing lights and headaches for several days at a time and was initially diagnosed with migraines. Despite close follow-up with multiple specialists, her vision problems progressed over this time. In addition to flashing lights, she c/o floaters and blurred vision. She was eventually diagnosed with AZOOR (acute zonal occult outer retinopathy). In May 2003, she developed left sided weakness along with gait instability. CSF revealed 13 RBC, 1 ...

424 JCPSP 2006, Vol. 16 (6): 424-425 I NTRODUCTION Primary non-Hodgkin’s lymphoma of the female genital tract is a rare condition, accounting for approximately 1% of primary extranodal lymphomas. 1 Freeman et al. in a review of 12447 cases of lymphoma , found only 10 cases related to the female genital tract. 2 NHL present insidiously. Majority present with painless superficial lymph adenopathy. Less commonly extranodal regions are the primary site of disease. Because of its rarity, no consensus exists on the management and treatment of primary NHL of the female genital tract. 3 Non-Hodgkin’s lymphoma usually affects older adults and, therefore, women are seldom found to have NHL when they are pregnant. C ASE HISTORY A 23 years old lady, married for the last 12 years, gravida 3 and para 2, reported ...

LEUKEMIA & LYMPHOMA Leukemia and lymphoma are cancers that originate in the bone marrow (makes different types of blood cells; white, red and platelets) or lymphatic tissues as the result of an acquired genetic injury to the DNA of a single cell, which becomes malignant and multiplies. Leukemia and lymphoma interfere with the production of healthy blood cells. Risk Factors • Chronic exposure to benzene or formaldehyde in the workplace • Exposure to doses of irradiation • Exposure to infectious agents • Cancer patients treated with certain cancer fighting drugs (chemotherapy) may develop leukemia. • Down syndrome (leukemia) • Myelodysplastic syndrome (blood disease linked to leukemia) • Human T-cell leukemia virus-1 – causes rare type of leukemia • Immune suppression • ...

TYPE OF CANCER: CD2-Positive T-Cell Lymphoma / Leukemia TYPE OF TRIAL: Phase I TRIAL SPONSOR: MedImmune PRINCIPAL INVESTIGATOR: Nam Dang M.D. CONTACT PERSON: Christine Zades (702) 822-5456 STUDY SUMMARY A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients with CD2- Positive T-Cell Lymphoma /Leukemia. TREATMENT OVERVIEW • There are no cycles for this study; patients just get treatment for 3 consecutive days/week, every other 16 weeks • There is no definite end point for this study • Patients should be seen by the physician at least every week PRE-TREATMENT ASSESSMENTS • CD2 IHC • HBsAg & HCV Testing • Serum IL-2 R alpha • ECG • PT/PTT • Urinalysis • CT Scan & Tumor Assessment • Tissue Biopsy/Aspirate • Bone Marrow Aspirate • Chest X-Ray ...

TYPE OF CANCER: Diffuse Large B-Cell Lymphoma TYPE OF TRIAL: Phase II TRIAL SPONSOR: Cell Therapeutics PRINCIPAL INVESTIGATOR: Nam Dang M.D. CONTACT PERSON: Carol Varela (702) 822-5449 STUDY SUMMARY A Phase II, Randomized, Multi-Center, Comparative Trail with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophophamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Elderly Patients with Diffuse Large B-Cell Lymophoma TREATMENT OVERVIEW • Each cycle is 21 days • There is a total of 8 cycles • Patient should be seen by the physician at least every 2-3 weeks. PRE-TREATMENT ASSESSMENTS • Lymph Node Biopsy and/or CT Guided Biopsy • Bone Marrow aspirate and biopsy • Lumbar puncture • MUGA • ECG • Serum cardiac Troponin T • CT/MRI of Chest/Abdomen/Pelvis ...

Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma : 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center Qi Liu, Luis Fayad, Fernando Cabanillas, Fredrick B. Hagemeister, Gregory D. Ayers, Mark Hess, Jorge Romaguera, M. Alma Rodriguez, Apostolia M. Tsimberidou, Srdan Verstovsek, Anas Younes, Barbara Pro, Ming-Sheng Lee, Ana Ayala, and Peter McLaughlin A B S T R A C T Purpose Advanced-stage follicular lymphoma is considered incurable. The pace of improvements in treatment has been slow. This article analyzes five sequential cohorts of patients with stage IV follicular lymphoma treated between 1972 and 2002. Methods Five consecutive studies (two were randomized trials) involving 580 patients were analyzed for overall survival (OS), failure-free survival (FFS), and survival ...

Risk of Second Malignancy After Non-Hodgkin’s Lymphoma : A British Cohort Study Nadejda Y. Mudie, Anthony J. Swerdlow, Craig D. Higgins, Paul Smith, Zongkai Qiao, Barry W. Hancock, Peter J. Hoskin, and David C. Linch A B S T R A C T Purpose To assess long-term site-specific risks of second malignancy following non-Hodgkin’s lymphoma (NHL) in relation to treatment and demographic factors. Patients and Methods A cohort of 2,456 patients with NHL who were first treated from 1973 to 2000 and were younger than 60 years from centers in the British National Lymphoma Investigation were observed, and occurrences of second malignancy was compared with expectations based on general population cancer rates in England and Wales. Results In total, 123 second malignancies occurred. Relative risks (RRs) were significantly elevated for all ...

> Croat Med J. 2006;47:515-9 Book Reviews Book Reviews Field of medicine: Molecular medicine. Format:Hardcoverbook. Audience: Biomedical research- ers, pharmacologists, pathologists, oncologists, hematologists, pedi- atricians, and other clinicians re- quiringregularscientificupdates. Purpose: To give information on current molecular methods and protocols used in the understand- ing, diagnosis, classification, and therapyoflymphoma. Content: The book consists of sixteen chapters, each beginning with a summary followed by a list of key words and the main text composed of introduction, ma- terials, methods, and final notes with references. The first chap- ter deals with apoptosis and Bcl- 2 family of proteins. After a short introduction, two protocols are described. The first protocol de- scribes the isolation ...

Lymphoma Manifesto Lymphatic Cancer Alliance November 2005 Page 2 E very hour of every day one person in the UK is diagnosed with lymphatic cancer. Around 45,000 people in the UK are living with the disease and incidence is rising. Given the appropriate treatment at the appropriate time, many lymphoma patients can have their disease managed effectively or even be cured. There have been huge advances in treatment which have resulted in more patients surviving, and with a better quality of life. However much remains to be done. This manifesto identifies the changes that are required throughout the patient journey if all today’s lymphoma patients, as well as the growing numbers who will have the disease in the future, are to receive the best treatment. If these changes are to be delivered, then greater resources will need to be allocated ...

lymphoma 1186 Mavic / Lymphoma Research Foundation Marathon Saturday, July 29 th 2006 9AM at Pedro’s Festival Name _ Age __ M F Address __ City State __ Zip __ Phone (__)Email Festival Attendee Fee $30 Additional donation $__ Total $ _ LRF Ride & ½ price Sat. Fest. Fee $50 Add’l donation $__ Total $ __ Payment cash__ check # Visa MasterCard AmEx Disc Card # __ Exp Date / Cardholder name 3 digit sec. code __ I hereby agree that in consideration of my participation in any or all of the events and activities associated with the Pedro's Mountain Bike Festival, hereafter ...

Meet the Specialist on Non-Hodgkin Lymphoma New Insights and Treatments Speaker: Robert O. Dillman, MD, FACP Medical & Scientific Director, Hoag Cancer Center, Newport Beach, CA Date: Friday, June 16, 2006 Time: 9:30-11:00am (Breakfast starts at 9:00am) Location: Medical Center of McKinney Goal To educate professionals on current treatment strategies and management trends being utilized to improve the treatment outcomes and quality of life of patients diagnosed with Non-Hodgkin Lymphoma (NHL). Educational Learning Objectives At the conclusion of this program, participants should be able to: Describe the pathophysiology and diagnosis of NHL; Discuss new treatment strategies offered for NHL patients; Understand clinical trial options available to treat NHL; Provide information on current options to manage the side effects of NHL therapies; Educate ...

Patients Against Lymphoma 3774 Buckwampum Road, Riegelsville PA 18077 Tel: 610-346-8419 Fax: 801-409-5736 Email: KarlS@Lymphomation.org STUDY PROPOSAL Combine molecular profiling research with evaluating first-line use of patient-specific idiotype cancer vaccines KEY BENEFITS: Acquire tissue once for multiple and complementary purposes. Avoid ethical issue of acquiring tissue solely for basic research. Quickly accrue patients for important clinical and basic research without precluding optimal benefit from standard treatment in future. BACKGROUND: Patient interest is an important starting point for study design. Patients with untreated stable disease provide an important untapped opportunity to investigate immune therapies, while also increasing our understanding of the molecular biology of the disease – which can provide the context for understanding outcomes, and the variable ...

Attribute Selection Methods Comparison for Classification of Diffuse Large B-Cell Lymphoma Helyane Bronoski Borges, and Júlio Cesar Nievola Abstract — The most important subtype of non-Hodgkin’s lymphoma is the Diffuse Large B-Cell Lymphoma . Approximately 40% of the patients suffering from it respond well to therapy, whereas the remainder needs a more aggressive treatment, in order to better their chances of survival. Data Mining techniques have helped to identify the class of the lymphoma in an efficient manner. Despite that, thousands of genes should be processed to obtain the results. This paper presents a comparison of the use of various attribute selection methods aiming to reduce the number of genes to be searched, looking for a more effective procedure as a whole. Keywords — Attribute selection, data mining. I. I NTRODUCTION NALYSIS ...

FOLIA HISTOCHEMICA ET CYTOBIOLOGICA Vol. 44, No. 1, 2006 pp. 43-47 Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes Tomasz Wróbel 1 , Grzegorz Mazur 1 , Piotr Dzie?giel 2 , Michal Jelen 3 , Andrzej Szuba 4 , Kazimierz Kuliczkowski 1 and Maciej Zabel 2 1 Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, 2 Department of Histology and Embryology, 3 Department of Pathology, and 4 Department of Internal Medicine and Occupational Diseases, Medical University, Wroclaw, Poland Abstract: Lymphatic vasculature in solid tumors may serve as the pathway for metastatic spread of the cancer to the regional lymph nodes and to distant ...

KIMBA ROXBY DOWNS (M) COOBER PEDY (DC) UNINCORP. FAR NORTH UNINCORP. FLINDERS RANGES ROBE BERRI CLARE HAWKER CEDUNA TANUNDA WHYALLA MENINGIE WILLUNGA MAITLAND PORT PIRIE BORDERTOWN PORT LINCOLN PETERBOROUGH PORT AUGUSTA MOUNT GAMBIER PORT BROUGHTON 0 100 200 50 Kms Lymphoma Mortality in South Australia, 1991-2000 by Statistical Local Areas GAWLER GLENELG MODBURY WILLUNGA ADELAIDE WOODVILLE ELIZABETH MOUNT BARKER BEDFORD PARK NOARLUNGA CENTRE Annual Mortality/100,000 0.0 - 5.0 5.1 - 7.5 7.6 - 10.0 10.1 - 20.0 Towns Statistical Local Areas Produced by: Data Analysis and Consulting Unit, Information Management Services, and Epidemiology Branch, Department of Human Services. Data Sources: Cancer Data ...

Unsuspected Lymphoma Diagnosed Using Biopsy During Kyphoplasty Folorunsho Edobor-Osula Dr. Joseph Lane Mentor EPI/BIOSTAT Dept or Program 2 Years in program BMS Judging Dept. Introduction: Kyphoplasty is now a widely performed procedure to treat vertebral compression fractures (VCF). In selecting appropriate patients for kyphoplasty, it is important to distinguish the pain caused by VCFs from other numerous causes of back pain. The differential diagnosis must consider not only osteoporosis, but also various causes of osteomalacia, endocrinopathy, and malignancy. It has recently been demonstrated that a biopsy taken during kyphoplasty confers no increased morbidity, and that even in the setting of normal laboratory values can identify patients with multiple myeloma. The purpose of this study was to determine the frequency of underlying metabolic malignant ...

FISH for Non-Hodgkin Lymphoma Using current World Health Organization criteria, the diagnosis and classification of non-Hodgkin lymphoma (NHL) requires cor- relation of morphologic findings with other ancillary data that may include cytogenetic findings. Several types of non-Hodgkin lymphoma are associated with specific, recurring cytogenetic abnormalities that are of diagnostic significance (1-3). Interphase fluorescence in situ hybridization (FISH) studies offer the ability to detect cytogenetic abnormalities in nondividing cells. FISH studies are especially valuable in lymph node or other solid tissue biopsies because they can be performed on for- malin-fixed, paraffin-embedded tissues and can, therefore, provide cytogenetic information even when material is not available for traditional banded karyotyping studies. The Reference Laboratory at The Cleveland Clinic offers FISH analysis for the following cytogenetic abnormalities: ...

Follicular Lymphoma Follicular Lymphoma Abstract L stage: imited IF-RT Watch and wait while asymptomatic CVP-R if symptomatic Page 2 Follicular Lymphoma Original Treatment Policy Prepared by Dr. Louise Bordeleau Updated April 2005 by Dr. Kevin Imrie & Dr. Matthew Cheung Updates: Rituximab combinations included as standard therapy Introduction Follicular lymphoma is the second most frequent type of non-Hodgkin’s lymphoma (NHL), accounting for 20-25% of all presentations [1]. The course of disease is often characterized by initial responses to therapy, but with inevitable relapses, sometimes with histologic transformation to aggressive histology NHL [2]. Thus, the disease is considered incurable and current treatment paradigms are focused on palliation of symptoms and minimizing treatment ...

Lymphoma of Bone Lymphoma of bone accounts for approximately seven per cent of all primary malignant tumors of bone and can be divided roughly into two clinical groups – Hodgkin’slymphoma of bone and non-Hodgkin’s lymphoma of bone. Hodgkin’s lymphoma of bone carries a much beter prognosis for survival. t tends to be localized and presents with a radiographic appearance that includes a dense, sclerotic response. The non-Hodgkin’s lymphomas can be divided into two categories. The systemic form, the most common form with generalized involvement of the entire lymphatic system including sof tissue and bone, carries a poor prognosis. The less common form that is found in bone and does not have systemic manifestations carries a beter prognosis for survival. To meet the strict criteria for a primary lymphoma of bone, disease must be contained within the skeletal system for at least six months before becoming disseminated ...

CORRESPONDENCE Angiogenesis and mast cells in Hodgkin lymphoma Leukemia advance online publication, 13 October 2005; doi:10.1038/sj.leu.2403992 TO THE EDITOR Hodgkin lymphoma (HL) differs from other lymphomas because the malignant cells, the Hodgkin and Reed–Sternberg (HRS) cells, are in minority and the majority of the tissue consists of surrounding benign cells, for example, eosinophilic granulo- cytes and mast cells, fibrosis and a varying number of microvessels. It has recently been reported that angiogenesis correlates to poor prognosis in HL. 1 We have previously reported that HL patients with many mast cells in their tumour tissue have a worse prognosis. 2 Mast cells produce functionally active CD30 ligand (CD30L) and the poorer prognosis has been proposed to be caused by a stimulation of HRS by CD30L. 3 Furthermore, we ...

Bulletin of Mathematical Biology 67 (2005) 79–99 www.elsevier.com/locate/ybulm A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma : investigation of the current protocol through theoretical modelling results B. Ribba a, 1 , K. Marron a , Z. Agur a, * , T. Alarcón b, 2 , P.K. Maini b a Institute for Medical BioMathematics, 10 Hate’ena Street, P.O.B. 282, 60991 Bene Ataroth, Israel b Centre for Mathematical Biology, Mathematical Institute, University of Oxford, 24–29 St. Giles’, Oxford OX1 3LB, UK Received 31 July 2003; accepted 17 June 2004 Abstract Doxorubicin treatment outcomes for non-Hodgkin’s lymphomas (NHL) are mathematically modelled and computationally analyzed. The NHL model includes a tumor structure incorporating mature ...

News Release, July 1, 2002, page 1 July1, 2002 – For Immediate Release World-Class Expert in the Field of Lymphoma Targets Joins Micromet’s Scientific Advisory Board Micromet AG, Martinsried / Planegg, Germany, today announces the appointment of Prof. Harald Stein to its Scientific Advisory Board (SAB) as of May 2002. Since 1984, Prof. Harald Stein is Professor of Pathology at the Freie Universität Berlin and Director and Chairman of the Institute of Pathology, University Hospital Benjamin Franklin. He brings more than 30 years of experience in human pathology and tumor staging and held various positions in medical research and academic teaching at the Universities of Kiel (Germany), Oxford (UK) and Berlin (Germany). Prof. Stein is renown for his extensive expertise on the cellular make-up of tumor tissues. He has substantially contributed to the characterization and classification of ...

Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma Immune function, believed to be important in lymphomagen- esis, is influenced by cross-talk between the endocrine and immune systems via hormones, such as oestrogen (reviewed in McMurray, 2001). Oestrogen has multiple effects on lympho- poietic cells including the modulation of lymphocyte growth, antigen presentation, and production of antibodies and cytokines (Olsen & Kovacs, 1996). Furthermore, oestrogen receptors are expressed in various hematopoietic cell types including lymphocytes, bone marrow and lymphoma cell lines. Therefore, the risk of lymphoproliferative diseases such as non- Hodgkin lymphoma (NHL) may be influenced by hormonal modulation. Few studies have examined the relationship between oestrogen exposure, reproductive factors and lym- phoma and published findings are contradictory (Nelson et al , ...

QC Form 0488 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7842.pdf Catalog #: 7842 – 100 µ g Concentration: 1 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Nonspecific Endonuclease/Nickase Activity: None detected after a 14–16 hr incubation of 1 µ g of RNA with 300 ng of supercoiled plasmid DNA, analyzed on an agarose gel. Exonuclease Activity: None detected after a 14–16 hr incubation of 1 µ g of RNA with 40 ng of 32 P-labeled Sau 3A fragments of pUC19, analyzed by PAGE. ...

QC Form 0489 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd. • Huntingdon, Cambridgeshire, UK • International Tel: 44(0) 1460 373 020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7843.pdf Catalog #: 7843 – 5 µ g Concentration: 0.5 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Functional Analysis: All Human poly(A) RNAs undergo accelerated stability testing. RNA integrity is checked both before and after a 14–18 hr incubation at 37 ° C and is visualized on a 1% denaturing agarose gel. Poly(A) RNAs are functionally tested by Northern blot analysis using Ambion’s NorthernMax Kit (Catalog #1940) and an ...